Latest news with #Optavia
Yahoo
7 days ago
- Business
- Yahoo
1 Safe-and-Steady Stock on Our Watchlist and 2 to Question
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. Luckily for you, StockStory helps you navigate which companies are truly worth holding. Keeping that in mind, here is one low-volatility stock that could succeed under all market conditions and two that may not deliver the returns you need. Rolling One-Year Beta: 0.22 Known for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast (NYSE:MED) has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods. Why Should You Dump MED? Products aren't resonating with the market as its revenue declined by 30.3% annually over the last three years Operating margin declined by 10.2 percentage points over the last year as its sales cratered Earnings per share have contracted by 27% annually over the last three years, a headwind for returns as stock prices often echo long-term EPS performance Medifast's stock price of $13.16 implies a valuation ratio of 0.4x forward price-to-sales. Dive into our free research report to see why there are better opportunities than MED. Rolling One-Year Beta: 0.77 Pioneering carbon-neutral flooring since its founding in 1973, Interface (NASDAQ:TILE) is a global manufacturer of modular carpet tiles, luxury vinyl tile (LVT), and rubber flooring that specializes in carbon-neutral and sustainable flooring solutions. Why Are We Out on TILE? Sales stagnated over the last five years and signal the need for new growth strategies Performance over the past five years shows each sale was less profitable, as its earnings per share fell by 3.5% annually Below-average returns on capital indicate management struggled to find compelling investment opportunities At $20.97 per share, Interface trades at 7.6x forward EV-to-EBITDA. If you're considering TILE for your portfolio, see our FREE research report to learn more. Rolling One-Year Beta: 0.74 Often located in suburban or semi-rural shopping centers, Ollie's Bargain Outlet (NASDAQ:OLLI) is a discount retailer that acquires excess inventory then sells at meaningful discounts. Why Is OLLI on Our Radar? Aggressive strategy of rolling out new stores to gobble up whitespace is prudent given its same-store sales growth Same-store sales growth averaged 4.1% over the past two years, showing it's bringing new and repeat shoppers into its stores Market share is on track to rise over the next 12 months as its 14.1% projected revenue growth implies demand will accelerate from its six-year trend Ollie's is trading at $112.16 per share, or 29.7x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-04-2025
- Business
- Yahoo
Personal Care Stocks Q4 Results: Benchmarking Medifast (NYSE:MED)
As the craze of earnings season draws to a close, here's a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at personal care stocks, starting with Medifast (NYSE:MED). While personal care products products may seem more discretionary than food, consumers tend to maintain or even boost their spending on the category during tough times. This phenomenon is known as "the lipstick effect" by economists, which states that consumers still want some semblance of affordable luxuries like beauty and wellness when the economy is sputtering. Consumer tastes are constantly changing, and personal care companies are currently responding to the public's increased desire for ethically produced goods by featuring natural ingredients in their products. The 13 personal care stocks we track reported a satisfactory Q4. As a group, revenues beat analysts' consensus estimates by 3.7% while next quarter's revenue guidance was 7% below. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 18.2% since the latest earnings results. Known for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast (NYSE:MED) has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods. Medifast reported revenues of $119 million, down 37.7% year on year. This print exceeded analysts' expectations by 4.2%. Despite the top-line beat, it was still a slower quarter for the company with revenue guidance for next quarter missing analysts' expectations and a significant miss of analysts' EBITDA estimates. 'This past year was a pivotal year for Medifast, as we continued to transform our business to meet the changing nature of a health and wellness market that has been revolutionized by the rising acceptance of GLP-1 medications,' said Dan Chard, Chairman & CEO. Medifast delivered the slowest revenue growth of the whole group. The stock is down 24.3% since reporting and currently trades at $12.21. Read our full report on Medifast here, it's free. Rising to fame on TikTok because of its 'bond building" hair products, Olaplex (NASDAQ:OLPX) offers products and treatments that repair the damage caused by traditional heat and chemical-based styling goods. Olaplex reported revenues of $100.7 million, down 9.8% year on year, outperforming analysts' expectations by 14.4%. The business had an incredible quarter with an impressive beat of analysts' EPS estimates and a solid beat of analysts' EBITDA estimates. Olaplex pulled off the biggest analyst estimates beat and highest full-year guidance raise among its peers. The market seems unhappy with the results as the stock is down 24.1% since reporting. It currently trades at $1.04. Is now the time to buy Olaplex? Access our full analysis of the earnings results here, it's free. With a portfolio boasting many household brands, Coty (NYSE:COTY) is a beauty products powerhouse spanning cosmetics, fragrances, and skincare. Coty reported revenues of $1.67 billion, down 3.3% year on year, falling short of analysts' expectations by 3.1%. It was a softer quarter as it posted a significant miss of analysts' EPS estimates and a miss of analysts' organic revenue estimates. Coty delivered the weakest performance against analyst estimates in the group. As expected, the stock is down 22.5% since the results and currently trades at $5.25. Read our full analysis of Coty's results here. Co-founded by actress Jessica Alba, The Honest Company (NASDAQ:HNST) sells diapers and wipes, skin care products, and household cleaning products. The Honest Company reported revenues of $99.84 million, up 10.6% year on year. This number beat analysts' expectations by 3.1%. It was a stunning quarter as it also logged an impressive beat of analysts' EPS estimates and a solid beat of analysts' EBITDA estimates. The stock is down 18.4% since reporting and currently trades at $4.64. Read our full, actionable report on The Honest Company here, it's free. Started on a kitchen table in Utah, Nature's Sunshine (NASDAQ:NATR) manufactures and sells nutritional and personal care products. Nature's Sunshine reported revenues of $118.2 million, up 8.5% year on year. This result surpassed analysts' expectations by 8.1%. Zooming out, it was a slower quarter as it produced a significant miss of analysts' EBITDA and EPS estimates. The stock is down 23.6% since reporting and currently trades at $11.17. Read our full, actionable report on Nature's Sunshine here, it's free. In response to the Fed's rate hikes in 2022 and 2023, inflation has been gradually trending down from its post-pandemic peak, trending closer to the Fed's 2% target. Despite higher borrowing costs, the economy has avoided flashing recessionary signals. This is the much-desired soft landing that many investors hoped for. The recent rate cuts (0.5% in September and 0.25% in November 2024) have bolstered the stock market, making 2024 a strong year for equities. Donald Trump's presidential win in November sparked additional market gains, sending indices to record highs in the days following his victory. However, debates continue over possible tariffs and corporate tax adjustments, raising questions about economic stability in 2025. Want to invest in winners with rock-solid fundamentals? Check out our Strong Momentum Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Sign in to access your portfolio
Yahoo
08-04-2025
- Business
- Yahoo
3 Reasons MED is Risky and 1 Stock to Buy Instead
What a brutal six months it's been for Medifast. The stock has dropped 29.3% and now trades at $13.05, rattling many shareholders. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation. Is now the time to buy Medifast, or should you be careful about including it in your portfolio? Dive into our full research report to see our analyst team's opinion, it's free. Even with the cheaper entry price, we don't have much confidence in Medifast. Here are three reasons why you should be careful with MED and a stock we'd rather own. Known for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast (NYSE:MED) has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods. Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last three years, Medifast's demand was weak and its revenue declined by 26.6% per year. This was below our standards and signals it's a low quality business. We track the change in earnings per share (EPS) because it highlights whether a company's growth is profitable. Sadly for Medifast, its EPS declined by 76.5% annually over the last three years, more than its revenue. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand. If you've followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can't use accounting profits to pay the bills. As you can see below, Medifast's margin dropped by 10.3 percentage points over the last year. Continued declines could signal it is in the middle of an investment cycle. Medifast's free cash flow margin for the trailing 12 months was 2.8%. We see the value of companies helping consumers, but in the case of Medifast, we're out. After the recent drawdown, the stock trades at 44× forward price-to-earnings (or $13.05 per share). At this valuation, there's a lot of good news priced in - we think there are better stocks to buy right now. We'd recommend looking at our favorite semiconductor picks and shovels play. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Sterling Infrastructure (+1,096% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
01-04-2025
- Business
- Yahoo
1 Consumer Stock with Exciting Potential and 2 to Turn Down
Consumer staples are considered safe havens in turbulent markets due to their inelastic demand profiles. Unfortunately, the sector hasn't provided much protection lately as it pulled back by 9.7% over the past six months. This drop was worse than the S&P 500's 2% loss. The elite companies can churn out earnings growth under any circumstance, however, and our mission at StockStory is to help you find them. With that said, here is one resilient consumer stock we've added to our cart and two we're passing on. Market Cap: $22.07 billion The classic red Heinz ketchup bottle's competitor, McCormick (NYSE:MKC) sells food-flavoring products like condiments, spices, and seasoning mixes. Why Is MKC Not Exciting? Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth Anticipated sales growth of 2.2% for the next year implies demand will be shaky Capital intensity has ramped up over the last year as its free cash flow margin decreased by 5.4 percentage points McCormick's stock price of $82.31 implies a valuation ratio of 26.3x forward price-to-earnings. If you're considering MKC for your portfolio, see our FREE research report to learn more. Market Cap: $143.7 million Known for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast (NYSE:MED) has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods. Why Do We Pass on MED? Products have few die-hard fans as sales have declined by 26.6% annually over the last three years Sales were less profitable over the last three years as its earnings per share fell by 76.5% annually, worse than its revenue declines Capital intensity has ramped up over the last year as its free cash flow margin decreased by 10.3 percentage points At $13.48 per share, Medifast trades at 45.7x forward price-to-earnings. Read our free research report to see why you should think twice about including MED in your portfolio, it's free. Market Cap: $101.5 billion Best known for its Marlboro brand of cigarettes, Altria (NYSE:MO) offers tobacco and nicotine products. Why Are We Fans of MO? Differentiated product offerings are difficult to replicate at scale and lead to a best-in-class gross margin of 69.9% Disciplined cost controls and effective management resulted in a strong two-year operating margin of 55.7% Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends Altria is trading at $60.10 per share, or 11.2x forward price-to-earnings. Is now the time to initiate a position? Find out in our full research report, it's free. The Trump trade may have passed, but rates are still dropping and inflation is still cooling. Opportunities are ripe for those ready to act - and we're here to help you pick them. Get started by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like United Rentals (+322% five-year return). Find your next big winner with StockStory today for free.
